These results were validated in a retrospective cohort of EGFR-mutant NSCLC patients who received a single line of EGFR TKI including osimertinib, with 20% of post-treatment samples having PPP3CB mRNA accumulation without any known genetic mechanism of acquired resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.